Innovent and AnHeart Report Interim Results of Taletrectinib (AB-106) in P-II TRUST Trial for the Treatment of ROS1-Positive NSCLC at CSCO 2021

September 27, 2021 Auto Bot Clinical Trials, Innovent, NSCLC, P-II 0

Shots:

  • The P-II TRUST trial evaluates taletrectinib (AB-106, ROS1/NTRK inhibitor) in 37 TKI-naïve or pre-treated patients with ROS1-positive NSCLC
  • As of June 16, 2021 cut off data, the therapy demonstrated an ORR (90.5% & 43.8%) & DCR (90.5% & 75.0%) in treatment-naïve & pre-treated patient. ROS1 G2032R resistant mutations were observed in three pre-treated patients & experienced tumor regression, 2 patients reported PR & 1 patient achieved SD
  • Additionally, patients with assessable brain metastasis pre-enrollment demonstrated intracranial ORR (83.3%) as assessed by the investigator. The therapy was safe with well- tolerated AEs

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Medicircle

The post Innovent and AnHeart Report Interim Results of Taletrectinib (AB-106) in P-II TRUST Trial for the Treatment of ROS1-Positive NSCLC at CSCO 2021 first appeared on PharmaShots.